STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.
STORM is backed by blue chip investors Cambridge Innovation Capital, Merck Ventures, Pfizer Ventures, Touchstone Innovations and Taiho Ventures LLC who share the founders’ ambitions to build a world-leading company in the field. To date, STORM Therapeutics has raised £16million of funding,
STORM Therapeutics was founded in 2015 and occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK.
Find out more about our: